Course: Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial
CME Credits: 1.00
Released: 2022-08-29
Remdesivir is a broad-spectrum antiviral that reduces hospitalization and may decrease mortality among noncritically ill inpatients with COVID-19., Remdesivir is not recommended for use in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min1.73 m2 owing to the presence of excipients that may accumulate in kidney dysfunction and worsen kidney or hepatic outcomes.
Educational Objective
To identify the key insights or developments described in this article
View Full Course